Display options
Cite
Troya J, Cuevas G, Ryan P, et al. Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients. Open Forum Infect Dis. 2017;4(3):ofx164doi: 10.1093/ofid/ofx164.
Troya, J., Cuevas, G., Ryan, P., Díez, V., Izquierdo, E., Escobar, I., & Solís, J. (2017). Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients. Open forum infectious diseases, 4(3), ofx164. https://doi.org/10.1093/ofid/ofx164
Troya, Jesús, et al. "Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients." Open forum infectious diseases vol. 4,3 (2017): ofx164. doi: https://doi.org/10.1093/ofid/ofx164
Troya J, Cuevas G, Ryan P, Díez V, Izquierdo E, Escobar I, Solís J. Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients. Open Forum Infect Dis. 2017 Aug 07;4(3):ofx164. doi: 10.1093/ofid/ofx164. eCollection 2017. PMID: 28948183; PMCID: PMC5604167.
Copy Download .nbib Format: NLM
Share it on

Open Forum Infect Dis. 2017 Aug 07;4(3):ofx164. doi: 10.1093/ofid/ofx164. eCollection 2017.

Infliximab Biosimilars: A Promising but Unusual Treatment for Mycobacterial Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients.

Open forum infectious diseases

Jesús Troya, Guillermo Cuevas, Pablo Ryan, Victorino Díez, Elsa Izquierdo, Ismael Escobar, Javier Solís

Affiliations

  1. Department of Internal Medicine.
  2. Medical Outpatient Care Unit, and.
  3. Department of Hospital Pharmacy, Hospital Universitario Infanta Leonor, Madrid, Spain.

PMID: 28948183 PMCID: PMC5604167 DOI: 10.1093/ofid/ofx164

Abstract

Immune reconstitution inflammatory syndrome can present as a paradoxical reaction after initiation of antiretroviral treatment in patients with severe immunosuppression and underlying infections. Immune reconstitution inflammatory syndrome has often been associated with mycobacteria, and the clinical response to traditional treatment with corticosteroids is not always satisfactory. Consequently, administration of an infliximab biosimilar could lead to an improvement in the clinical status of these patients.

Keywords: HIV; IRIS; infliximab biosimilar; mycobacteria

References

  1. Curr Opin HIV AIDS. 2010 Nov;5(6):504-10 - PubMed
  2. Future Microbiol. 2015;10(6):1077-99 - PubMed
  3. EJC Suppl. 2013 Dec;11(3):1-11 - PubMed
  4. Aliment Pharmacol Ther. 2017 Apr;45(8):1043-1057 - PubMed
  5. Clin Infect Dis. 2004 Dec 1;39(11):1709-12 - PubMed
  6. Curr HIV/AIDS Rep. 2012 Sep;9(3):238-50 - PubMed
  7. Semin Immunol. 2014 Jun;26(3):203-9 - PubMed
  8. J Autoimmun. 2017 May;79:4-16 - PubMed
  9. AIDS. 2012 Oct 23;26(16):2110-2 - PubMed
  10. Int J Infect Dis. 2015 Mar;32:39-45 - PubMed
  11. Clin Infect Dis. 2016 Jan 15;62(2):258-261 - PubMed
  12. Drugs. 2000 Jun;59(6):1341-59 - PubMed
  13. Clin Infect Dis. 2009 Jan 1;48(1):101-7 - PubMed
  14. AIDS. 2010 Sep 24;24(15):2381-90 - PubMed
  15. Clin Infect Dis. 2008 Nov 15;47(10 ):e83-5 - PubMed

Publication Types